(Reuters) - The world's second-largest biotechnology company also slightly boosted its full-year profit forecast, but shares inched down as healthy but largely in-line sales of key products failed to excite investors waiting for Genentech's next big revenue driver.
"It seems like Genentech is in a bit of a holding pattern for the time being," said Cowen and Co analyst Eric Schmidt, who has said Avastin colon cancer trial results expected next year were one of the next key events for the company.
Read more at Reuters.com Hot Stocks News
"It seems like Genentech is in a bit of a holding pattern for the time being," said Cowen and Co analyst Eric Schmidt, who has said Avastin colon cancer trial results expected next year were one of the next key events for the company.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment